Browse by Phase
Phase 1 / Phase 2 Clinical Trials
Phase 1/2 combined trials evaluate both safety (Phase 1) and preliminary efficacy (Phase 2) in a single study protocol, often used to accelerate early development.
Total Trials
393
Recruiting Now
393
Top Conditions in Phase 1 / Phase 2
Frequently Asked Questions — Phase 1 / Phase 2 Trials
What are combined Phase 1/2 clinical trials?
Phase 1/2 trials are adaptive designs that evaluate both safety (Phase 1 objectives) and preliminary efficacy (Phase 2 objectives) within a single trial protocol. They are commonly used in oncology and rare disease research to accelerate development timelines. Dose escalation occurs in the Phase 1 portion, followed by expansion cohorts at the selected dose in the Phase 2 portion.
Why do sponsors combine Phase 1 and Phase 2?
Combining phases reduces development time and cost, particularly for conditions with high unmet need. For rare diseases or cancer indications, finding sufficient eligible patients can be challenging—a combined design uses the same patient pool more efficiently. Regulatory agencies including the FDA encourage adaptive designs to accelerate evidence generation for serious conditions.
How do I find Phase 1/2 trials I can join?
Phase 1/2 trials listed on ClinicalMetric are sourced from ClinicalTrials.gov and filtered by recruitment status. Each listing shows enrollment status, conditions studied, sponsor, participating sites, and estimated enrollment. Because Phase 1/2 trials often have narrow eligibility criteria, carefully review the protocol and discuss potential participation with your treating physician.
Active Phase 1 / Phase 2 Studies
NCT06683885 Phase 1, Phase 2
Recruiting
A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabin...
Condition
Newly Diagnosed Diffuse Large B-cell Lymphoma
Enrollment
80 pts
Location
China
Sponsor
Mingzhi Zhang
NCT07539155 Phase 1, Phase 2
Recruiting
Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancrea...
Condition
Borderline Resectable/Unresectable Pancreatic Cancer
Enrollment
20 pts
Location
United States
Sponsor
University of Arkansas
NCT05698147 Phase 1, Phase 2
Recruiting
Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
Condition
Central Nervous System Lymphoma
Enrollment
30 pts
Location
China
Sponsor
Tong Chen, MD
NCT07636798 Phase 1, Phase 2
Recruiting
Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First...
Condition
Biliary Tract Cancer
Enrollment
20 pts
Location
China
Sponsor
West China Hospital
NCT04752774 Phase 1, Phase 2
Recruiting
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With...
Condition
Spasticity
Enrollment
240 pts
Location
United States, Austria, Bulgaria
Sponsor
Ipsen
NCT04299191 Phase 1, Phase 2
Recruiting
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advan...
Condition
High-grade Glioma
Enrollment
28 pts
Location
United States
Sponsor
Laminar Pharmaceuticals
NCT07229638 Phase 1, Phase 2
Recruiting
A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-98...
Condition
Solid Tumor
Enrollment
70 pts
Location
China
Sponsor
Suzhou Suncadia Biopharmaceuti
NCT07049055 Phase 1, Phase 2
Recruiting
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-pacli...
Condition
Pancreatic Cancer, Metastatic
Enrollment
144 pts
Location
United States
Sponsor
Engeneic Pty Limited
NCT06364774 Phase 1, Phase 2
Recruiting
ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia
Condition
Beta-Thalassemia
Enrollment
12 pts
Location
United States
Sponsor
Children's Hospital of Philade
NCT06173219 Phase 1, Phase 2
Recruiting
Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Mal...
Condition
Advanced Solid Tumor
Enrollment
38 pts
Location
China
Sponsor
China-Japan Friendship Hospita
NCT07244705 Phase 1, Phase 2
Recruiting
A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally ...
Condition
Colorectal Cancer (Diagnosis)
Enrollment
66 pts
Location
Australia, Taiwan
Sponsor
Anbogen Therapeutics, Inc.
NCT06389877 Phase 1, Phase 2
Recruiting
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With A...
Condition
Alpha 1-Antitrypsin Deficiency
Enrollment
106 pts
Location
United States, Australia, Ireland
Sponsor
Beam Therapeutics Inc.
NCT06885281 Phase 1, Phase 2
Recruiting
A Study of ZL-1310 in Participants With Selected Solid Tumors
Condition
Solid Tumors
Enrollment
166 pts
Location
United States, China
Sponsor
Zai Lab (Shanghai) Co., Ltd.
NCT05910827 Phase 1, Phase 2
Recruiting
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docet...
Condition
Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Enrollment
398 pts
Location
Australia, Moldova, Singapore
Sponsor
Hummingbird Bioscience
NCT06187402 Phase 1, Phase 2
Recruiting
A Study of LM-24C5 For Advanced Solid Tumors
Condition
Advanced Solid Tumor
Enrollment
49 pts
Location
United States
Sponsor
LaNova Medicines Limited
NCT06193902 Phase 1, Phase 2
Recruiting
LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.
Condition
Tumor, Solid
Enrollment
17 pts
Location
United Kingdom
Sponsor
Leucid Bio
NCT06471946 Phase 1, Phase 2
Recruiting
VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS
Condition
Higher-risk Myelodysplastic Syndromes
Enrollment
54 pts
Location
China
Sponsor
Navy General Hospital, Beijing
NCT07362095 Phase 1, Phase 2
Recruiting
Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem...
Condition
Acute Leukemia
Enrollment
46 pts
Location
China
Sponsor
Zhujiang Hospital
NCT06603844 Phase 1, Phase 2
Recruiting
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
Condition
Solid Tumor
Enrollment
156 pts
Location
United States, United Kingdom
Sponsor
Corbus Pharmaceuticals Inc.
NCT05828511 Phase 1, Phase 2
Recruiting
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerat...
Condition
Multiple Myeloma
Enrollment
149 pts
Location
United States, France, Spain
Sponsor
Regeneron Pharmaceuticals
NCT07193719 Phase 1, Phase 2
Recruiting
Influence of Personalized Lung Volume Optimization Maneuver on Lung Function and...
Condition
Congenital Heart Disease
Enrollment
80 pts
Location
Germany
Sponsor
Charite University, Berlin, Ge
NCT06975410 Phase 1, Phase 2
Recruiting
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR O...
Condition
EGFR Overexpression
Enrollment
80 pts
Location
South Korea
Sponsor
Yuhan Corporation
NCT04785196 Phase 1, Phase 2
Recruiting
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma...
Condition
Liposarcoma
Enrollment
95 pts
Location
China
Sponsor
Ascentage Pharma Group Inc.
NCT05938465 Phase 1, Phase 2
Recruiting
Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in ...
Condition
Ileal Pouch
Enrollment
50 pts
Location
United States
Sponsor
Exegi Pharma, LLC
NCT07113067 Phase 1, Phase 2
Recruiting
Accelerated rTMS vs. Sham for Stroke Apathy
Condition
Apathy
Enrollment
40 pts
Location
United States
Sponsor
Medical University of South Ca
Page 1 of 16 — 393 trials total
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology